Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)

Dose-ascending, Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH)

Double-blind, randomized, placebo and active controlled dose-ascending study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of ACP-001 (TransCon PEG hGH).

Inclusion Criteria:

• Healthy male subjects
• 20 to 45 years old
• Body Mass Index of 18.5 kg/m2 and less than or equal to 29.9 kg/m2
• Others

Exclusion Criteria:

• Known history of hypersensitivity to human growth hormone (hGH)
• Known history of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, hematological, immunological, hepatic or renal disease, or malignancies
• Others